Generate Biomedicines raises $700.0M Series C (United States, Jun 2026)
Reach the investors backing rounds like this
Backed by Nvidia, Amgen · verified emails and LinkedIn on Datapile
Nvidia invests in Generate Biomedicines, targeting $1.8T market with AI-driven drug discovery - Crypto Briefing
Generate Biomedicines is a biotech startup focused on AI-driven drug discovery, specifically in the generation and optimization of therapeutic proteins. The company aims to significantly reduce the time required for drug discovery, with a pipeline that includes a Phase 3 clinical trial for severe asthma and multiple oncology candidates with FDA Fast Track designation.
Nvidia invests in Generate Biomedicines, targeting $1.8T market with AI-driven drug discovery Crypto Briefing
| Sep 23, 2026 | Ema | $77.0M | Series B | United States |
| Sep 23, 2026 | Baselayer | $35.0M | Series A | United States |
| Sep 23, 2026 | Hubble Network | $200.0M | Series C | United States |
| Sep 23, 2026 | Topdog | $2.5M | Seed | United States |
21,380 investors back startups in United States
You just read who funded Generate Biomedicines. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.